Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Leber Congenital Amaurosis, Sorsby Fundus Dystrophy, Usher Syndrome Type 2A, and Doyne Honeycomb Retinal Dystrophy.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. Her top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy.

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Mira M. Sachdeva, M.D., Ph.D. specializes in the medical and surgical management of diseases of the retina, including diabetic retinopathy, macular degeneration, retinal vascular occlusions, retinal detachments, macular holes, and epiretinal membranes. Her research efforts are directed towards developing new treatments to prevent or reverse the retinal neurodegeneration and vision loss that occurs in patients with diabetes. Dr. Sachdeva’s ultimate goal is to identify strategies for neuroprotection that are broadly applicable to other conditions in which the retina is irreversibly damaged, including macular degeneration and retinal detachment. Dr. Sachdeva received her medical degree from the University of Pennsylvania medical school. She completed her residency at the Wilmer Eye Institute in 2014. Thereafter, she completed a fellowship at the Massachusetts Ear and Eye Infirmary. Dr. Sachdeva is currently a Wilmer Rising Professor in Ophthalmology. Videos Dr. SachdevaOphthalmology Recent News Articles and Media Coverage Bridging the Gap, Wilmer Magazine (July 2019). Dr. Sachdeva is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. Her top areas of expertise are Diabetic Retinopathy, Retinal Detachment, Adult-Onset Vitelliform Macular Dystrophy (AVMD), Late-Onset Retinal Degeneration, and Vitrectomy.

Elia J. Duh, M.D., is the G. Edward and G. Britton Durell Professor of Ophthalmology at the Wilmer Eye Institute. He has a joint appointment in the Department of Chemical and Biomolecular Engineering, The Whiting School of Engineering. He specializes in diseases of the retina, including diabetic retinopathy and age-related macular degeneration. In addition to his clinical practice, Dr. Duh actively researches the molecular mechanisms underlying diabetic retinopathy and macular degeneration, particularly the process of ocular neovascularization and excessive retinal vascular permeability. His research has helped determine the role of the major antioxidant regulator, Nrf2, in retinal diseases, and also connected Nrf2 to lifespan. His work has also provided insights into the involvement of the eye in COVID-19. Dr. Duh’s interest in developing new treatments for retinal diseases includes nanomedicine approaches for targeted drug delivery to the eye. Dr. Duh graduated summa cum laude from Yale University and obtained his medical degree from Harvard Medical School. He completed his ophthalmology residency and medical retina fellowship at the Wilmer Eye Institute. He was elected to the American Society of Clinical Investigation in 2016. Dr. Duh is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Vitrectomy.

James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval. Dr. Handa is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy.

Fernando Arevalo is an Ophthalmologist in Baltimore, Maryland. Dr. Arevalo is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Gyrate Atrophy of the Choroid and Retina, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Diabetic Retinopathy.

Jefferson Doyle, M.D., Ph.D., M.H.S. specializes in pediatric ophthalmology and genetic eye diseases and is the recipient of the 2023 Andreas C. Dracopoulos & Daniel Finkelstein, M.D. Rising Professorship in Ophthalmology. His main focus is pediatric and juvenile forms of cataracts, glaucoma, anterior segment dysgenesis, and ectopia lentis. His genetics interests include Marfan syndrome and related connective tissue disorders, complex inherited forms of strabismus in both children and adults (e.g. CFEOM, Duane syndrome), and pediatric retinal dystrophies. Dr. Doyle has published extensively on a number of genetic disorders over the past decade, holds several patents for novel therapeutic approaches to treat them, and has given many national and international talks about them. Dr. Doyle's main research focus is understanding the genetic causes and molecular mechanisms driving genetic diseases, and utilizing that knowledge to develop new therapeutic strategies for them. Over the past decade, he has played a significant role in advancing our understanding of Marfan syndrome and related connective tissue disorders. His work and that of collaborators has led to the discovery of the genetic causes of Shprintzen-Goldberg syndrome and Loeys-Dietz like syndrome. His work has also led to a much better understanding of the molecular mechanisms driving Marfan syndrome, and he holds two patents for novel therapeutic strategies to treat it. Part of his current work focuses on the identification of genes that protect people from developing a number of genetic disorders, and leveraging that knowledge to develop new therapies for those diseases. He also has an interest in pediatric myopia, and has ongoing pre-clinical studies seeking to understand the mechanisms that may drive it and the development of novel therapeutic strategies to treat it. Recent News Articles and Media Coverage A Center for Genetic Eye Disease, Wilmer Insider (Oct. 2021). Dr. Doyle is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Duane-Radial Ray Syndrome, Ehlers-Danlos Syndrome (EDS), Vascular Ehlers-Danlos Syndrome (VEDS), and Strabismus.

Peter L. Gehlbach, M.D., Ph.D. is the J. Willard Marriott, Jr. Professor of Ophthalmology with joint appointment in the Department of Electrical and Computer Engineering, The Whiting School of Engineering. A member of the Wilmer faculty since 2000, he was recruited by a national search to become the inaugural Maumenee Scholar at Johns Hopkins University School of Medicine. His clinical practice is composed of international, national, and regional patient populations with the most complex retinal disease. An expert vitreoretinal surgeon, Dr. Gehlbach has been a leader in performing and teaching complex surgical cases that require coordination with multiple ophthalmological specialists. His research interests include cutting-edge surgical approaches to patients with retinal disease and the development of novel surgical tools and approaches to retinal microsurgery. Dr. Gehlbach’s work has been supported by multiple NIH grants and prestigious foundations with research published in numerous peer-reviewed journals and presented at ophthalmology conferences around the world. The founding director of the former Wilmer Gene Therapy Vector Center, he has served as the director of the Wilmer Echography Center as well as the Retina Fellowship Training Program at Johns Hopkins. He holds multiple patents in both the U.S. and abroad. Dr. Gehlbach received his B.A. and M.D. degrees from the University of Vermont, and his Ph.D. in cell and integrative physiology from the University of Minnesota. He completed an internship and residency training in general surgery at the University of Health Sciences, Chicago Medical School. His ophthalmology residency was at Washington University in St. Louis, where he also completed a fellowship in protein chemistry. He completed a medical and surgical retina fellowship at the Casey Eye Institute in Portland. Dr. Gehlbach is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Detachment, Retinal Vein Occlusion, and Vitrectomy.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Timothy D. Polk, MD, specializes in comprehensive ophthalmology. He is affiliated with UPMC Memorial. Dr. Polk completed his fellowships at the University of Iowa Hospitals and Clinics and Bascom Palmer Eye Institute, residency at Greater Baltimore Medical Center and medical degree at the University of Virginia School of Medicine. Dr. Polk is rated as an Advanced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Artery Occlusion, Retinal Vein Occlusion, and Vitrectomy.

Janet Sunness is an Ophthalmologist in Baltimore, Maryland. Dr. Sunness is rated as a Distinguished provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. Her top areas of expertise are Stargardt Macular Degeneration, Geographic Atrophy, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). Dr. Sunness is currently accepting new patients.

Joseph Harlan is an Ophthalmologist in Lutherville, Maryland. Dr. Harlan is rated as a Distinguished provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Retinal Artery Occlusion, and Age-Related Macular Degeneration (ARMD). Dr. Harlan is currently accepting new patients.

George Agritellis is an Ophthalmologist in Baltimore, Maryland. Dr. Agritellis is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Cataract, Meibomianitis, Glaucoma, and Eyelid Bump. Dr. Agritellis is currently accepting new patients.

Kenneth Taubenslag is an Ophthalmologist in Baltimore, Maryland. Dr. Taubenslag is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Endophthalmitis, Neuroretinitis, Uveitis, Trabeculectomy, and Vitrectomy. Dr. Taubenslag is currently accepting new patients.

Eric Singman is an Ophthalmologist in Baltimore, Maryland. Dr. Singman is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Papilledema, Ehlers-Danlos Syndrome (EDS), Strabismus, and Optic Neuritis. Dr. Singman is currently accepting new patients.

Lisa Schocket is an Ophthalmologist in Baltimore, Maryland. Dr. Schocket is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. Her top areas of expertise are Diabetic Retinopathy, Retinal Detachment, Age-Related Macular Degeneration (ARMD), and Late-Onset Retinal Degeneration. Dr. Schocket is currently accepting new patients.

Steven Bernstein is an Ophthalmologist in Baltimore, Maryland. Dr. Bernstein is rated as an Experienced provider by MediFind in the treatment of Doyne Honeycomb Retinal Dystrophy. His top areas of expertise are Glaucoma, Increased Intracranial Pressure, Adult-Onset Vitelliform Macular Dystrophy (AVMD), and Optic Neuritis. Dr. Bernstein is currently accepting new patients.